Go Pro
NASDAQ:JBIO

Jade Biosciences Q2 2025 Earnings Report

Jade Biosciences logo
$21.34 +0.04 (+0.19%)
Closing price 07/14/2026 04:00 PM Eastern
Extended Trading
$22.00 +0.66 (+3.09%)
As of 07:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Jade Biosciences EPS Results

Actual EPS
-$0.86
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.43
One Year Ago EPS
N/A

Jade Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Jade Biosciences Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
7:00AM ET

Jade Biosciences Earnings Headlines

Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to move out of overpriced AI stocks before the tech trade breaks down and into lesser-known names with real potential to challenge the Mag 7. One pick he calls 'an upgrade to Tesla stock' is a little-known company that just inked a partnership with Nvidia, positioning it ahead of Tesla in the autonomous vehicle race.tc pixel
See More Jade Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jade Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jade Biosciences and other key companies, straight to your email.

About Jade Biosciences

Jade Biosciences (NASDAQ:JBIO) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation. Preclinical studies have demonstrated promising activity in models of atopic dermatitis, psoriasis‐associated itch and other dermatologic conditions, supporting the progression of these candidates into human trials. Jade Biosciences’ pipeline strategy includes both topical and systemic formulations to broaden the therapeutic scope across multiple indications.

Founded in the mid‐2010s and incorporated in Delaware, Jade Biosciences maintains its headquarters in New Haven, Connecticut. The company’s management team draws on experience from established pharmaceutical and biotechnology organizations, combining expertise in medicinal chemistry, dermatology and clinical development. Listed on the Nasdaq under the ticker JBIO, Jade Biosciences is working to advance its pipeline through clinical milestones while preparing for potential partnerships and regulatory filings in the United States and other key markets.

View Jade Biosciences Profile